SCHEMBL230407

SCHEMBL230407

NC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1NCc1ccco1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
CA12 O43570 2/20 0.55
CA1 P00915 2/20 0.55
CA2 P00918 2/20 0.55
CA4 P22748 2/20 0.55
HTR1A P08908 1/20 0.55
CA6 P23280 1/20 0.55
HSD11B1 P28845 1/20 0.55
CA5A P35218 1/20 0.55
CA7 P43166 1/20 0.55
SLC10A1 Q14973 1/20 0.55
CA9 Q16790 1/20 0.55
GPR35 Q9HC97 1/20 0.55
CISD1 Q9NZ45 1/20 0.55
CA14 Q9ULX7 1/20 0.55
ABCG2 Q9UNQ0 1/20 0.55
CA5B Q9Y2D0 1/20 0.55
APP P05067 8/20 0.53
AURKA O14965 1/20 0.43
RPS6KB1 P23443 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL229073 0.77 CA12 (0.85) ALDH1A1CA12CA1CA2CA4
SCHEMBL4284511 0.76 APP (0.51) ALDH1A1CA12CA1CA2CA4
SCHEMBL27846292 0.75 APP (0.45) ALDH1A1CA12CA1CA2CA4
SCHEMBL6534763 0.74 ALDH1A1 (0.64) ALDH1A1CA12CA1CA2CA4
SCHEMBL29436041 0.73 APP (0.60) ALDH1A1CA12CA1CA2CA4
SCHEMBL27827634 0.73 ALDH1A1 (0.44) ALDH1A1CA12CA1CA2CA4
SCHEMBL232377 0.72 ALDH1A1 (0.50) ALDH1A1CA12CA1CA2CA4
SCHEMBL11819699 0.71 APP (0.80) ALDH1A1CA12CA1CA2CA4
Furosemide SCHEMBL29406913 0.71 CISD1 (1.00) ALDH1A1CA12CA1CA2CA4
SCHEMBL2880956 0.71 CA12 (0.83) ALDH1A1CA12CA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004225-A1 BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE NEUROTHERAPEUTICS PHARMA, INC. (US) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004225-A1 BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE ABCG2, ABCB1, TRPV1 ALDH1A1 1389/4885CA12 2528/4885CA1 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.